

Design and biological evaluation of synthetic
retinoids: probing length vs. stability vs. activityCite this: *Mol. Biosyst.*, 2013,
9, 3124Graeme Clemens,^a Kevin R. Flower,^b Peter Gardner,^a Andrew P. Henderson,^c
Jonathan P. Knowles,^c Todd B. Marder,^{cd} Andrew Whiting^{*c} and
Stefan Przyborski^{*ef}

All *trans*-retinoic acid (ATRA) is widely used to direct the differentiation of cultured stem cells. When exposed to the pluripotent human embryonal carcinoma (EC) stem cell line, TERA2.cl.SP12, ATRA induces ectoderm differentiation and the formation of neuronal cell types. We report in this study that novel polyene chain length analogues of ATRA require a specific chain length to elicit a biological responses of the EC cells TERA2.cl.SP12, with synthetic retinoid AH61 being particularly active, and indeed more so than ATRA. The impacts of both the synthetic retinoid AH61 and natural ATRA on the TERA2.cl.SP12 cells were directly compared using both RT-PCR and Fourier Transform Infrared Micro-Spectroscopy (FT-IRMS) coupled with multivariate analysis. Analytical results produced from this study also confirmed that the synthetic retinoid AH61 had biological activity comparable or greater than that of ATRA. In addition to this, AH61 has the added advantage of greater compound stability than ATRA, therefore, avoiding issues of oxidation or decomposition during use with embryonic stem cells.

Received 10th July 2013,
Accepted 2nd October 2013

DOI: 10.1039/c3mb70273a

www.rsc.org/molecularbiosystems

Introduction

There are over 4000 retinoids, both natural and synthetic, structurally and often biochemically related to vitamin A.¹ All-*trans*-retinoic acid 1 (ATRA), the major metabolite of vitamin A, and its two isomers, 9-*cis*-retinoic acid 2 (9CRA) and 13-*cis*-retinoic acid 3 (13CRA), have essential roles in many biological processes during both chordate embryogenesis and adult homeostasis.^{2,3} These include cellular differentiation, proliferation and apoptosis,⁴ embryonic development⁵ and vision.⁶ Due to the ability of retinoids to control differentiation and apoptosis in both normal and tumour cells, they have the potential to act as chemopreventative and chemotherapeutic agents, although toxicity has prevented widespread use.^{7,8} ATRA and other commercially available retinoids are, however, used to treat dermatological conditions.⁹

The use of retinoic acids as inducers of cell differentiation has some limitations, exemplified by ATRA which readily isomerises resulting in mixtures of ATRA, 9CRA, 13CRA and other species.¹⁰ This instability derives from the five conjugated double bonds that absorb light in the 300–400 nm region, which can occur under laboratory lighting conditions.^{11–14} Murayama *et al.*¹¹ reported that isomers of ATRA differently affect the ability of mammalian stem cells to differentiate along alternative lineages. Consequently this can lead to the differential regulation of alternative key molecular pathways involved in cellular development, which can result in increased heterogeneity within cultures of differentiating stem cells.^{15,16} In order to increase reproducibility in the differentiation process, stable retinoid derivatives are desirable, an approach adopted by us.¹⁰ These types of stable compounds can maintain a constant concentration in the culture system, and are readily stored and handled. This is preferable to the alternative approach of attempting to reduce the sensitivity of ATRA to isomerisation by the use of additives such as bovine serum albumin (BSA), fibrogen, lysozyme, phosphatidylcholine *N*-ethylmaleimide and vitamin C.^{17,18} None of these additives completely suppress isomerisation, and indeed, they may affect cellular processes on their own.

Retinoic acids contain three major characteristic regions: a bulky hydrophobic section; a conjugated variable linker; and a carboxylic acid end group (Fig. 1). Extensive modifications to all three regions are possible^{1,19} and we reported the incorporation of an aromatic ring to replace parts of the polyene chain,

^a Manchester Institute of Biotechnology, Manchester University, 131 Princess Street, Manchester, M1 7DN, UK^b School of Chemistry, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK^c Department of Chemistry, Durham University, Science Laboratories, South Road, Durham, DH1 3LE, UK. E-mail: andy.whiting@durham.ac.uk^d Institut für Anorganische Chemie, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074 Würzburg, Germany^e Department of Biological Sciences, Durham University, Science Laboratories, South Road, Durham, DH1 3LE, UK. E-mail: stefan.przyborski@durham.ac.uk^f Reinnervate Ltd., NETPark Incubator, Thomas Wright Way, Sedgefield, TS21 3FD, UK





Fig. 1 Structures for ATRA **1**, 9CRA **2**, 13CRA **3**, generic retinoid structure, EC23 (4-position CO₂H) and EC19 (3-position CO₂H).

forming a class of retinoids sometimes termed arotinoids.^{10,19} Another common alteration is the inclusion of a 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene unit as a substitute for the trimethylcyclohexenyl ring and part of the polyene chain, as this removes metabolic oxidation sites.^{19–22} Also, an acetylene moiety has been successfully employed to act as a non-isomerisable conjugated linker unit while retaining, or even enhancing, biological activity in systems such as EC23 **4a** (Fig. 1).¹⁰ Interestingly, biological characterisation of EC23 **4a** demonstrated its ability to induce neural tissues, which contrasts with EC19 **4b** which also induced cell differentiation, the latter resulting primarily in epithelial cells with only few neural phenotypes.¹⁰ These results indicated that subtle differences in molecular structure can have dramatic effects on the biological response. In this paper, we contrast these findings with recent work on the design, synthesis, stability and biological activity of a series of new synthetic retinoids designed to be closer in structure to the natural systems **1–3**, but with some of the increased stability of **4a**. With these types of compounds we expected to be able to probe further the effects polyene chain length and stability *versus* their effect on cellular development processes, particularly in stem cells or models of stem cell differentiation.


Results and discussion

Preparation of retinoid analogues

It was envisaged that through a series of cross-coupling reactions, including Heck–Mizoroki and Sonogashira processes, we would be able to obtain compounds of varying size to undertake a focussed structure activity relationship (SAR) study. Alkyne **5** was prepared as a generic synthon, starting with iodination of 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene, followed by cross-coupling to TMSA under Sonogashira conditions and finally deprotection according to optimised procedures previously reported.¹⁰ The synthesis of the different polyene chains with varying lengths began with the treatment of methyl tetrolate **6** with sodium iodide in acetic acid^{23,24} to provide *Z*-3-iodobut-2-enoic acid methyl ester **7** in 89% yield and 100% stereoselectivity. Generation of the *E*-isomer **8** was achieved through isomerisation of the *Z*-isomer with hydroiodic acid in benzene^{24,25} to give 3-*E*-iodobut-2-enoic acid methyl ester **8** in a 66% yield (Scheme 1).



Scheme 1 Synthesis of iodide **8** from methyl tetrolate **6**.



Scheme 2 Synthesis of synthetic retinoids **9**, **12** (AH61) and **14** starting with iodide **8** and acetylene **5**.

The *E*-isomer was subsequently used in two separate reactions: (1) direct coupling to acetylene **5** allowing for the formation of ‘short’ retinoid-like analogue **9**; and (2) Heck–Mizoroki coupling to vinylboronate ester **10**, followed by iododeboronation, leading to a dienyliodide **11** for further elaboration to longer derivatives as outlined in Scheme 2, which employs an iterative Heck–Mizoroki coupling¹⁶ with boronate **10** and highly stereoselective iododeboronation methodology.¹⁷ Subsequent, Sonogashira couplings of iodides **11** and **13** to acetylene **5** under standard conditions^{26,27} provided esters **12** (known as AH61) and **14** in 76 and 64% yields, respectively. Saponification^{28,29} of the methyl esters produced the corresponding carboxylic acids **12** (AH61) and **14** in 85 and 87% yields, respectively (Scheme 2).

Stability of the synthetic retinoids *versus* natural ATRA

With the series of synthetic retinoids **9**, **12** (AH61) and **14** in hand, their photostability was tested and compared to that of ATRA. We have previously shown, by using ¹H NMR spectroscopy, that ATRA was susceptible to photoisomerisation and degradation when exposed to laboratory (fumehood) fluorescent light in the visible to near-UV range. After three days exposure, substantial isomerisation/degradation occurred with approximately 37% of ATRA remaining.¹⁰ When the synthetic retinoids **9**, **12** (AH61) and **14** were exposed to the same wavelength of fluorescent light and their ¹H NMR spectra compared with control (un-irradiated) samples, the severity of the isomerisation depended greatly upon the length of the conjugated linker. The short analogue **9** remained completely unaltered, with 100% of the original compound present (Fig. 2). The ‘ATRA-like’ analogue **12** (AH61) showed signs of isomerisation to one other isomer identified as (*E,Z*) but still retained 86% of the original compound and, more importantly, showed no signs of degradation unlike as previously reported for ATRA (Fig. 3). As one might predict, the extended






Fig. 2 ^1H NMR at 400 MHz of **9** in DMSO-d_6 (5.0–8.5 ppm region) in: top – in the absence of light and; bottom – after 3 days exposure to white fluorescent light at a distance of 40 cm.




Fig. 3 ^1H NMR at 400 MHz of **12** (AH61) in DMSO-d_6 (5.0–8.5 ppm region) in: top – in the absence of light and; bottom – after 3 days exposure to white fluorescent light at a distance of 40 cm.




Fig. 4 ^1H NMR at 400 MHz of **14** in DMSO-d_6 (5.0–8.5 ppm region) in: (A) the absence of light and; (B) after 3 days exposure to white fluorescent light at a distance of 40 cm.

analogue **14** was shown to be the least stable, with isomerisation not dissimilar to that seen for ATRA (Fig. 4). The inherent instability of ATRA lies within the conjugated linker region, as previously established, and replacement of sections of the polyene chain with both an acetylene moiety and phenyl rings as for EC23 **4a** provides complete stability. The stability of the systems **9**, **12** (AH61) and **14** reported here varies as a function of polyene chain length, though there is a significant improvement in stability compared to similarly sized retinoic acids.

Effect of the novel retinoids on human pluripotent stem cells

Having prepared the series of synthetic retinoids **9**, **12** (AH61) and **14**, they were assessed for their ability to induce differentiation

carried out using a human embryonal carcinoma (EC) cell line. EC cells are the stem cells of teratocarcinomas, and therefore, retain their ability to differentiate into one or more of the embryonic germ layers. One of the earliest and most frequently used human EC cell lines is the TERA2 cell line, originally isolated from a lung metastasis originating from a testicular germ cell tumour.³⁰ A subsequent sub-clone culture, termed TERA2.cl.SP12, was developed in 2001 by immunomagnetic isolation followed by single cell selection and culture.³¹ This cell line was chosen for our study, because it has been shown to differentiate in response to ATRA. After 21 days of co-culture with ATRA a heterogeneous cell population was visualised containing multiple mature functioning neurons.^{32–34} Consequently, this makes the TERA2.cl.SP12 cell line an effective model system for the *in vitro* study of neurogenesis.

To compare the effect of the synthetic retinoids **9**, **12** (AH61) and **14** versus both known natural retinoid responses and other synthetic retinoids previously synthesised within the group, cultures of TERA2.cl.SP12 EC cells were incubated with 10 μM concentrations of each compound synthesised. Simultaneously, control cultures were assessed consisting of untreated, therefore undifferentiated, cells along with cultures exposed to the vehicle, DMSO. Induction of cellular differentiation in response to the synthetic retinoids was initially evaluated by analysing the expression profile of known markers for both stem cell and differentiated phenotypes (Fig. 5). Flow cytometry analysis was performed at 3, 7 and 14 days on cell samples, treated with 10 μM ATRA, **9**, **12** (AH61) and **14**. The cells were analysed for the expression of the stem cell antigens, SSEA-3 (globoseries stage specific embryonic antigen-3) and TRA-1-60 (keratin-sulfate-associated glycoprotein stem surface marker), whereby a decrease in the expression level of SSEA-3 and TRA-1-60 indicates cells committing to differentiation. Simultaneously, as cell lines of the TERA2 lineage are well characterised in their ability to form neurons in response to ATRA (33,34), flow cytometry was also used to assess the expression of A2B5 (ganglioseries antigen marking early-stage neural cells), a marker which is expressed during the early stages of neuronal development. Similar expression profiles were visualised for **12** (AH61) as were seen for ATRA over the 14 day period (Fig. 5). In cell cultures treated with the short and extended analogues **9** and **14**, expression levels of SSEA-3 and TRA-1-60 remained relatively high with A2B5 staying comparatively low. Consequently, cultures treated with **9** and **14** were cultured for only 7 days and not through to 14 days due to overgrowth (Fig. 5). As both **9** and **14** did not induce any significant degree of cellular differentiation, all further studies were centred on the ATRA-sized analogue **12** (AH61).

Further assessment of cellular differentiation in response to synthetic retinoid **12** was evaluated through the expression profiles of known genes. Samples from the cells analysed by flow cytometry at 3, 7 and 14 days after treatment with 10 μM concentrations of retinoids were simultaneously analysed through RT-PCR. Three genes of interest were chosen, *i.e.* Nanog and Oct-4, as gatekeepers of pluripotency, and Pax-6 as a motor and ventral neural phenotype. The expression of Nanog and Oct-4 was suppressed in cultures treated with both






Fig. 5 Flow cytometric analysis of the induction of TERA2.cl.SP12 cell differentiation in response to retinoids. Markers of stem cells (SSEA-3 and TRA-1-60, A and B respectively) and neural differentiation (A2B5, C) were differentially regulated during the 14 day culture period in response to 10 μ M ATRA, 9, 12 and 14. Both ATRA and 12 (AH61) resulted in a rapid decrease in expression of the stem cell markers and reciprocal increase in neural marker expression after 14 days. Treatment with 9 and 14 did not induce differentiation; cells continued to proliferate and the experiment was terminated after 7 days as a results of being over-confluent. Data represent mean \pm SEM, $n = 3$.

ATRA and analogue 12 (AH61), all in a similar manner (Fig. 6). Consistent with these observations, Pax-6 expression increased




Fig. 6 RT-PCR analysis of the induction of TERA2.cl.SP12 cell differentiation in response to retinoids. Genes associated with pluripotency (Nanog and Oct 4, A and B respectively) and motor and ventral neural phenotype (Pax 6, C) were differentially regulated during the 14 day culture period in response to 10 μ M ATRA and 12 (AH61). Both ATRA and 12 (AH61) resulted in a rapid decrease in expression of the pluripotency genes and reciprocal increase in the motor and ventral neural gene after 14 days. Data represent mean \pm SEM, $n = 3$.

to up to and just after day 7, after which it decreased slightly to day 14. Again both natural retinoid and synthetic analogue showed a similar profile (Fig. 6).

IR imaging of human pluripotent stem cells treated with novel retinoid derivatives

Results from the biological assays, Fig. 5 and 6, clearly show that the synthetic retinoid 12 (AH61) and ATRA induce the differentiation of the TERA2.cl.SP12 cells in a similar manner, whereas, retinoids 9 and 14 do not. Recently, Clemens *et al.*³⁵ successfully used Fourier Transform Infrared Microspectroscopy (FT-IRMS) coupled with multivariate analysis to distinguish TERA2.cl.SP12 cells from their differentiating derivatives. An infrared absorption spectrum of a molecule is characteristic of the structure and bonding within the molecule and thus represents a molecular fingerprint. The infrared spectrum of a biological cell contains a superposition of spectra from all the molecules within the cell and, although these cannot be separated, the overall pattern is nevertheless characteristic of






Fig. 7 (a) PC-LDA analysis, 2 PCs extracted, spectra transformed to second derivative and then auto-scaled. Histograms display where the DMSO and synthetic retinoid **12** (AH61) treated TERA2.cl.SP12 cells lie in the LDA 1 scores plot after 7 days; (b) (upper curve) LDA 1 spectral loading, which shows the wavenumbers that contribute to the separation seen from the PC-LDA analysis (lower curves) mean spectra of the DMSO and **12** (AH61) treated cells (fingerprint spectral range); (c) mean spectral comparison of the DMSO and **12** (AH61) treated cells (protein spectral range). (Note that a positive absorption band will appear as a negative “peak” in the second derivative but at the same wave-number position as the original.)

the cell. The technique can therefore be used to identify different cell types or to identify induced cellular changes such as differentiation. Accordingly, we used FT-IRMS to further assess and validate the biological activity of synthetic retinoid **12** (AH61).

Fig. 7(a) shows that cells, 7 days after treated synthetic retinoid **12** (AH61), can be distinguished from the pluripotent stem cells using FT-IRMS coupled with Principle Component Linear Discriminant Analysis (PC-LDA). The biochemical changes of the differentiating cells are described in Fig. 7(b).

In the LDA 1 spectral loading, Fig. 7(b), absorption increases at wavenumbers associated with proteins (1234, 1286, 1315, 1337 cm^{-1}) can be seen from cells treated with **12** (AH61) when compared to those of the undifferentiated stem cells.³⁶ Protein changes can also be seen from the mean spectral differences shown as second derivatives in Fig. 7(c). The negative “peaks” at 1640 and 1660 cm^{-1} (components of the amide I band which is very sensitive to secondary protein structure) are indicative of beta sheet and alpha helix structure, respectively. Clearly, the cells treated with **12** (AH61) have an increased level of alpha helix structure proteins compared with the control TERA2.cl.SP12 stem cells.

The LDA 1 spectral loading also shows decreases in absorption associated with RNA at 1120 (symmetric stretching of the phosphodiester band of RNA)³⁷ and 1367–1369 cm^{-1}




Fig. 8 (a) PC-LDA of TERA2.cl.SP12 cells treated with ATRA (green), EC23 (blue) and **12** (AH61) (cyan) at day 7, 3 PCs extracted (b) PC-LDA of TERA2.cl.SP12 cells treated DMSO (black), ATRA (green), EC23 (blue) and **12** (AH61) (cyan) at day 7, 10 PCs extracted.



(C–N stretching vibration associated with cytosine and guanine).³⁶ These overall changes in net RNA and protein content from the cells treated with **12** (AH61) may be a sign of mRNA stores being used up and transcription occurring to direct the synthesis of specific proteins as a result of induction and progression of cellular differentiation.

Spectra recorded from the TERA2.cl.SP12 cells treated with **12** (AH61) were also compared against cells treated with ATRA, and EC23, at 7 days using PC-LDA, Fig. 8. The LDA scores plot clearly shows that spectra recorded from the retinoid treated cells (blue, cyan, green) can be distinguished from the pluripotent stem cells (black) in LDA scores space. Fig. 8 and 9 also show that the TERA2.cl.SP12 cells treated with both ATRA and the

synthetic retinoid **12** (AH61) are biochemically similar, 7 days after the introduction of the retinoids indicated by the virtual overlap of the cyan and green data. This in agreement with both the flow cytometry and RT-PCR analysis results seen in Fig. 5 and 6, respectively.

Biological assays, such as flow cytometry and RT-PCR, are seen as the industry standard and are commonly used when discriminating stem cells from their differentiating derivatives. However, these biological assays can be laborious and have been shown to have some drawbacks.³⁸ Results seen from the FT-IRMS analysis are in agreement with those seen from the biological assays and these were achieved without intensive sample preparation, relatively cheaply, and very importantly, quickly. As an infrared absorption spectrum of a cell contains information of the macromolecular composition, protein, lipid, carbohydrate and nucleic acid changes from differentiating cells can be explained. This therefore shows the potential of FT-IRMS in screening stem cells and their differentiating derivatives. The information obtained can be seen as complementary to biological assays when investigating cell differentiation and understanding cellular development. Because of the speed of FT-IRMS, it is possible that it may be favoured when looking at the effect of new synthetic retinoids on known embryonic model systems.

Summary and conclusions

Our findings further underline the value of understanding how the structure of retinoid analogues relates to their biological activity. In this study we report on the importance of polyene chain length in relation to compound stability and their effect on cellular differentiation by human pluripotent stem cells. Increasing the polyene chain length resulted in enhanced compound instability and levels of isomerisation proportional to the degree of such structural modification. Lengthening of the polyene linker region resulted in isomerisation not dissimilar to that seen for ATRA. In terms of induction of biological activity, a short chain length did not provoke a biological response (compound **9**). The longest chain length we tested (compound **14**) induced only a small partial cellular response that was most likely the result of a mixture of compounds produced from the isomerised parent molecule. In relation to the molecular structures tested, the optimal structure of the polyene linker region appears to be of medium chain length [compound **12** (AH61)] in between that of retinoids **9** and **14**. Using conventional molecular methods and FT-IRMS, we showed that synthetic retinoid **12** (AH61) showed biological activities comparable to ATRA. However unlike ATRA, compound **12** (AH61) remained mostly intact during the compound stability tests and showed only mild isomerisation.

In conclusion, we have further demonstrated how understanding the structure activity relationship of synthetic retinoids plays an important role in compound design. Moreover, compound **12** (AH61) represents a potentially useful tool for biological investigations avoiding the issues of severe compound isomerisation experienced by ATRA whilst conserving a high level of biological activity.




Fig. 9 Mean spectral comparisons of ATRA, **12** and DMSO treated TERA2.cl.SP12 cells: (a) lipid spectral range (2830–3010 cm^{−1}); (b) fingerprint spectral range (1000–1475 cm^{−1}) (c) protein spectral range (1475–1760 cm^{−1}).



Experimental

General synthetic chemistry

All cross-couplings were carried out under an argon atmosphere using standard Schlenk techniques unless otherwise stated. Other reactions were performed in the air in reagent-grade solvents. The compound 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene acetylene **5** was prepared according to the literature.¹⁰ Trimethylsilylacetylene was obtained from Fluorochem, methyl propiolate and methyl tetrolate from Aldrich, and 4,4,6-trimethyl-2-vinyl-1,3,2-dioxaborane **10** from Frontier Scientific.

Dry solvents were dried by the use of a commercial solvent purification system (SPS). Petroleum ether (40:60) refers to the fraction of petroleum ether that boils between 40 and 60 °C. Where mixtures of solvents have been used for chromatography, the ratios given refer to volumes used. Thin layer chromatography (TLC) was performed on Polygram SIL G/UV254 plastic backed silica gel plates. Visualisation was achieved using a UV lamp at 254 nm, or staining with basic potassium permanganate. Column chromatography was carried out at medium pressure using silica gel, 40–60 µm, 60 Å obtained from Alfa Aesar. ¹H NMR spectra were obtained in CDCl₃, unless otherwise stated, at 400, 500 or 700 MHz on Varian Mercury-400, Varian Inova-500 or Varian VNMRs 700 MHz spectrometers respectively. Spectra are reported as chemical shift δ (ppm) (number of protons, multiplicity, coupling constant J (Hz), assignment). All peaks are reported using the residual protic solvent peak of CHCl₃ ($\delta_{\text{H}} = 7.26$ ppm), as an internal reference. ¹³C NMR spectra were obtained in CDCl₃ at either 126 or 176 MHz on Varian Inova-500 or Varian VNMRs 700 MHz spectrometers, respectively. All peaks are reported using the residual protic solvent peak of CHCl₃ ($\delta_{\text{C}} = 77.00$ ppm) as an internal reference. ¹¹B NMR spectra were recorded at 128 MHz on a Bruker Avance-400 spectrometer in ppm with respect to external BF₃·OEt₂. IR spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR Spectrometer. EI-MS analyses were performed on an Agilent 6890N GC equipped with a 5973N MSD Performance Turbo CI running an EI mode, and an Anatune Focus Autosampler/liquid handler, using UHP helium as the carrier gas. ES-MS analyses were performed on a Thermo-Electron Corp. Finnigan LTQ-FT mass spectrometer, using the electrospray in positive ion mode (ES+) to generate ions. Elemental analyses were obtained using an Exeter Analytical CE-440 analyser. Melting points were obtained using a Gallenkamp melting point apparatus.

(Z)-3-Iodobut-2-enoic acid methyl ester 7. Methyl tetrolate **6** (900 mg, 9.2 mmol), NaI (2.4 g, 16 mmol) and acetic acid (6 mL) were heated to reflux for 1.5 h, poured onto water (20 mL) and extracted with ether (2 × 30 mL). The combined organic extracts were washed with saturated NaHCO₃ (3 × 20 mL), 5% Na₂S₂O₃ (20 mL) and brine (20 mL). Drying (MgSO₄) and evaporation yielded (Z)-3-iodobut-2-enoic acid methyl ester **7** as a clear oil (1.87 g, 90%). All spectroscopic and analytical properties were identical to those reported in the literature.³⁹

(E)-3-Iodobut-2-enoic acid methyl ester 8. A solution of (Z)-3-iodobut-2-enoic acid methyl ester **7** (4.38 g, 19.4 mmol) and HI (0.25 g, 1.94 mmol) in benzene (40 mL) were heated to

reflux for 48 h and then allowed to cool to room temperature. The mixture was partitioned between water (100 mL) and ether (150 mL), followed by the aqueous phase being extracted with ether (2 × 25 mL). The combined organic phases were then washed with saturated NaHCO₃ (50 mL), 5% Na₂S₂O₅ (50 mL) and brine (50 mL). Drying (MgSO₄) and evaporation yielded the crude as a pale yellow oil. Purification by silica gel chromatography (EtOAc:pet. ether, 5:95, as eluent) yielded (E)-3-iodobut-2-enoic acid methyl ester as a colourless oil (1.10 g, 25%) and recovered (Z)-3-iodobut-2-enoic acid methyl ester (2.90 g, 66%). All spectral and analytical properties were identical to those reported in the literature.³⁹

(2E,4E)-3-Methyl-5-(4,4,6-trimethyl-[1,3,2]-dioxaborinan-2-yl)-penta-2,4-dienoic acid methyl ester. To a dried Schlenk tube under a positive pressure of argon was added (E)-3-iodobut-2-enoic acid **8** methyl ester (0.941 g 4.16 mmol), dry MeCN (15 mL), Pd(OAc)₂ (47 mg, 0.21 mmol), tri(*o*-tolyl)phosphine (128 mg, 0.42 mmol), AgOAc (758 mg, 4.54 mmol) and vinylboronate **10** (752 mg, 0.81 mL, 4.88 mmol), the mixture degassed using freeze-pump-thaw method (3 ×) and heated to 55 °C with vigorous stirring. After 22 h the mixture was cooled, diluted with Et₂O (80 mL), passed through Celite, washed with 5% HCl (20 mL), water (40 mL) and brine (40 mL). Drying (MgSO₄) and evaporation gave the crude product as a orange oil. Purification by silica gel chromatography (EtOAc:pet. ether, 1:9 as eluent) gave (2E,4E)-3-methyl-5-(4,4,6-trimethyl-[1,3,2]-dioxaborinan-2-yl)-penta-2,4-dienoic acid methyl ester (780 mg, 74%) as a clear oil; $\nu_{\text{max}}/\text{cm}^{-1}$ 2976, 2359, 1710, 1596, 1393, 1327, 1290, 1229 and 1153; ¹H NMR (700 MHz, CDCl₃) δ_{H} 1.28 (3H, d, $J = 6$, CH₃), 1.30 (3H, s, CH₃), 1.31 (3H, s, CH₃), 1.51 (1H, t, $J = 13$, CH₂), 1.80 (1H, dd, $J = 13$ and 2.5, CH₂), 2.25 (3H, d, $J = 1$, CH₃), 3.70 (3H, s, OCH₃), 4.21–4.27 (1H, m, CH), 5.87 (1H, s, CH), 5.93 (1H, d, $J = 18$, CH) and 6.92 (1H, d, $J = 18$, CH); ¹³C NMR (176 MHz, CDCl₃) δ_{C} 13.5, 23.3, 28.3, 31.4, 46.1, 51.3, 65.2, 71.3, 121.0, 129–130, 149.2, 153.2, 167.8; ¹¹B NMR (128 MHz, CDCl₃) δ_{B} 26 (br s); m/z (ES) 252.1643 (M^+ , C₁₃H₂₁BO₄, requires 252.1642). 237, 221, 196, 152, 137, 124 and 83.

Methyl (2E,4E)-5-iodo-3-methylpenta-2,4-dienoate 11. To a dried Schlenk tube under a positive pressure of argon was added a solution of the (2E,4E)-3-methyl-5-(4,4,6-trimethyl-[1,3,2]-dioxaborinan-2-yl)-penta-2,4-dienoic acid methyl ester (700 mg, 2.78 mmol), in dry THF (10 mL), and the tube cooled to –78 °C in the absence of light. NaOMe (6.91 mL of a 0.5 M solution in MeOH, 3.46 mmol) was added dropwise and the mixture stirred for 30 min, followed by the addition of ICl (4.67 mL of a 1.0 M solution in DCM, 4.67 mmol) dropwise. The mixture was stirred for 1 h, warmed to room temperature, diluted with Et₂O (80 mL), washed with 5% sodium metabisulphite (30 mL), water (30 mL) and brine (30 mL). Drying (MgSO₄) and evaporation gave the crude product as a orange oil. Purification by silica gel chromatography (EtOAc:pet. ether, 1:9, a eluent), gave the product as a clear oil, which slowly crystallised as an off-white solid (602 mg, 86%); all spectral and analytical properties were identical to those reported in the literature.³⁹ $\nu_{\text{max}}/\text{cm}^{-1}$ 3070, 3013, 2943, 1708, 1612, 1433, 1386, 1359, 1234, 1190 and 1153; ¹H NMR (400 MHz, CDCl₃) δ_{H} 2.24



(3H, d, $J = 1.2$, CH₃), 3.71 (3H, s, OCH₃), 5.74 (1H, q, $J = 0.8$, CH), 6.89 (1H, d, $J = 15$, CH), 7.10 (1H, d, $J = 15$, CH); ¹³C NMR (126 MHz, CDCl₃) δ_C 13.6, 51.5, 84.8, 120.0, 148.5, 151.4, 167.2; m/z (EI) 252 (M⁺), 221, 193, 126 and 125.

(2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid methyl ester. The dienyl iodide **11** (500 mg, 1.98 mmol), 6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene **5** (509 mg, 2.40 mmol) and triethylamine (10 mL) were added to a dried Schlenk tube and the mixture degassed using the freeze-pump-thaw method (3 \times). Pd(OAc)₂ (22 mg, 0.10 mmol), PPh₃ (52 mg, 0.19 mmol) and CuI (38 mg, 0.19 mmol), were then added and the mixture degassed by freeze-pump-thaw (3 \times). The mixture was stirred at room temperature for 5 h, diluted with EtOAc (80 mL), passed through Celite, washed with 5% HCl (20 mL 2 \times), brine (20 mL), dried (MgSO₄) and concentrated. Purification by silica gel chromatography (pet. ether:EtOAc, 95:5, as eluent) gave (2E,4E)-2-methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid methyl ester as a yellow oil (510 mg, 76%); $\nu_{\max}/\text{cm}^{-1}$ 2956, 2192, 1715, 1608, 1490, 1434, 1358, 1232 and 1154; ¹H NMR (500 MHz, CDCl₃) δ_H 1.27 (6H, s, 2 \times CH₃), 1.28 (6H, s, 2 \times CH₃), 1.68 (4H, s, 2 \times CH₂), 2.31 (3H, d, $J = 1.2$, CH₃), 3.73 (3H, s, OCH₃), 5.84 (1H, s, CH), 6.24 (1H, d, $J = 16$, CH), 6.70 (1H, d, $J = 16$, CH), 7.21 (1H, dd, $J = 1.5$ and 8, Ar), 7.26 (1H, d, $J = 8$, Ar), 7.41 (1H, d, $J = 1.5$, Ar); ¹³C NMR (126 MHz, CDCl₃) δ_C 13.4, 31.9, 32.0, 34.5, 34.6, 35.1, 35.1, 51.5, 87.6, 96.0, 114.7, 120.1, 120.4, 127.0, 128.9, 130.3, 143.7, 145.4, 146.3, 151.4, 167.4; m/z (ES) 337.2164 (M + H⁺, C₂₃H₂₉O₂, requires 337.2162), 337, 305 and 215.

(2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid **12 (AH61).** (2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid methyl ester (0.51 g, 1.49 mmol), was dissolved in a THF water mixture (3:1, 20 mL) followed by the addition of LiOH·H₂O (250 mg, 5.94 mmol). The mixture was stirred at room temperature for 48 h in the absence of light after which the reaction was judged to be complete by tlc. The mixture was then acidified to pH 1 by the addition of HCl (20%), and extracted with diethyl ether (20 mL, 2 \times). The sample was evaporated to give the crude product as a yellow powder. This was re-crystallised from acetonitrile to yield the product as a yellow crystalline solid (394 mg, 82%); m.p. 205.1–206.7 °C; $\nu_{\max}/\text{cm}^{-1}$ 2500–3500, 2194, 1679, 1604, 1488, 1459, 1255 and 1185; ¹H NMR: (700 MHz, CDCl₃) δ_H 1.27 (6H, s, 2 \times CH₃), 1.28 (6H, s, 2 \times CH₃), 1.68 (4H, s, 2 \times CH₂), 2.32 (3H, d, $J = 1$, CH₃), 5.87 (1H, s, CH), 6.29 (1H, d, $J = 16$, CH), 6.73 (1H, d, $J = 16$, CH), 7.21 (1H, dd, $J = 1.5$ and 8, Ar), 7.27 (1H, d, $J = 8$, Ar), 7.41 (1H, d, $J = 1.5$, Ar); ¹³C NMR: (126 MHz, CDCl₃) δ_C 13.6, 31.9, 32.0, 34.4, 34.6, 35.1, 35.1, 87.5, 96.6, 115.6, 119.9, 120.0, 127.0, 129.0, 130.3, 143.5, 145.4, 146.4, 153.7, 172.0; m/z (ES) 321.1858 (M⁺, C₂₂H₂₆O₂, requires 321.1860), 260, 186, 159 and 91; anal. calcd for C₂₂H₂₆O₂: C, 81.95; H, 8.13. Found: C, 81.87; H, 8.10.

(E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester. To a dried Schlenk flask under a positive pressure of argon was added (E)-3-iodobut-2-enoic acid methyl ester **11** (0.36 g, 1.72 mmol),

6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene **5** (0.40 g, 1.88 mmol) and Et₃N (10 mL). The mixture was degassed using the freeze-pump-thaw method (3 \times), followed by the addition of Pd(OAc)₂ (20 mg, 0.08 mmol), PPh₃ (44 mg, 0.16 mmol) and CuI (32 mg, 0.16 mmol). The mixture degassed using the freeze-pump-thaw method (2 \times) and stirred at room temperature under argon. After 24 h, the reaction was diluted with Et₂O (80 mL), passed through Celite, washed with 5% HCl (20 mL, 2 \times), brine (20 mL), dried (MgSO₄) and evaporated to give an orange oil. Purification by silica gel chromatography (EtOAc:petroleum ether, 5:95, as eluent) gave (E)-3-methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester as a pale yellow oil (530 mg, 99%). $\nu_{\max}/\text{cm}^{-1}$ 2957, 2195, 1715, 1612, 1433, 1342, 1269, 1198, 1180 and 1135; ¹H NMR (700 MHz, CDCl₃) δ 1.27 (6H, s, 2 \times CH₃), 1.28 (6H, s, 2 \times CH₃), 1.68 (4H, s, 2 \times CH₂), 2.40 (3H, d, $J = 1.5$, CH₃), 3.73 (3H, s, OCH₃), 6.15 (1H, q, $J = 1.5$, CH), 7.21 (1H, dd, $J = 8$ and 1.5, Ar), 7.27 (1H, d, $J = 8$, Ar), 7.41 (1H, d, $J = 1.5$, Ar); ¹³C NMR (176 MHz, CDCl₃) δ_C 20.3, 31.9, 32.0, 34.5, 34.7, 35.1, 35.1, 51.5, 90.5, 94.9, 119.4, 123.4, 127.0, 129.2, 130.5, 138.8, 145.5, 146.8, 166.9; m/z (ES) 311.2011 (M + H⁺, C₂₁H₂₇O₂, requires 311.2006). 279.

(E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-pent-2-en-4-ynoic acid **9.** (E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester (85 mg, 0.274 mmol) was added to a stirred solution of lithium hydroxide (46 mg, 1.10 mmol) in THF-H₂O (3:1, 20 mL) at room temperature. After 48 hours the reaction was judged to be complete and acidified to pH 1 to 2 by 20% HCl, extracted with ether (20 mL), dried (MgSO₄) and concentrated to give an off-white solid. Recrystallisation from acetonitrile yielded the product as an off-white crystalline solid (25 mg, 31%). $\nu_{\max}/\text{cm}^{-1}$ 2912, 2197, 1688, 1602, 1428, 1296, 1225 and 1145; ¹H NMR (700 MHz, CDCl₃) δ 1.27 (6H, s, 2 \times CH₃), 1.28 (6H, s, 2 \times CH₃), 1.68 (4H, s, 2 \times CH₂), 2.41 (3H, d, $J = 1.5$, CH₃), 6.18 (1H, d, $J = 1.5$, CH), 7.22 (1H, dd, $J = 8$ and 1.5, Ar), 7.28 (1H, d, $J = 8$, Ar), 7.42 (1H, d, $J = 1.5$, Ar); ¹³C NMR (176 MHz, CDCl₃) δ_C 20.6, 31.9, 32.0, 34.5, 34.7, 35.0, 35.1, 90.5, 96.2, 119.3, 122.4, 127.1, 129.2, 130.6, 141.3, 145.5, 147.0, 169.0; m/z (ES) 296.1773 (M⁺, C₂₀H₂₄O₂, requires 296.1771), 279, 255, 84 and 43.

(2E,4E,6E)-3-Methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester. To a dried Schlenk tube under a positive pressure of argon was added Pd(OAc)₂ (16.5 mg, 0.07 mmol), AgOAc (296 mg, 1.61 mmol), tri(*o*-tolyl)-phosphine (45 mg, 0.148 mmol), methyl (2E,4E)-5-iodo-3-methylpenta-2,4-dienoate (0.37 g, 1.47 mmol) and acetonitrile (10 mL). The mixture was degassed using the freeze-pump-thaw method (2 \times) followed by the addition of vinyl boronate **10** (265 mg, 1.72 mmol). The mixture was degassed again using the freeze-pump-thaw method before heating to 50 °C with vigorous stirring. After 22 h, the reaction was cooled to room temperature, diluted with Et₂O (60 mL), passed through Celite, washed with 5% HCl (20 mL), water (40 mL) and brine (20 mL), dried (MgSO₄) and evaporated. The product was purified by silica gel chromatography (EtOAc:pet. ether, 1:9, as eluent) to



give the product (2*E*,4*E*,6*E*)-3-methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester as a pale yellow oil (274 mg, 67%). $\nu_{\max}/\text{cm}^{-1}$ 2973, 1711, 1614, 1391, 1303, 1237, and 1150; ^1H NMR (700 MHz, CDCl_3) δ_{H} 1.28 (3H, d, $J = 6$, CH_3), 1.31 (3H, s, CH_3), 1.31 (3H, s, CH_3), 1.51 (1H, t, $J = 14$, CH_2), 1.80 (1H, dd, $J = 14$ and 3, CH_2), 2.30 (3H, s, CH_3), 3.71 (3H, s, OCH_3), 4.21–4.27 (1H, m, CH), 5.68 (1H, d, $J = 17$, CH), 5.81 (1H, s, CH), 6.36 (1H, d, $J = 17$, CH), 6.63 (1H, dd, $J = 17$ and 11, CH) and 6.99 (1H, dd, $J = 17$ and 11, CH); ^{13}C NMR (176 MHz, CDCl_3) δ_{C} 13.9, 23.3, 28.3, 31.4, 46.1, 51.2, 65.1, 71.1, 119.9, 130.0, 132.0, 136.6, 137.9, 146.0, 152.6, 167.5; m/z (ES) 278.1802 (M^+ , $\text{C}_{15}\text{H}_{24}\text{BO}_4$, requires 278.1798), 190, 174, 162, 144, 136, 58, 52 and 44.

(2*E*,4*E*,6*E*)-7-Iodo-3-methyl-hepta-2,4,6-trienoic acid methyl ester 13. To a dried Schlenk tube under a positive pressure of argon was added the (2*E*,4*E*,6*E*)-3-methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester (0.2 g, 0.72 mmol) in dry THF (5 mL). The mixture was cooled to -78°C in the absence of light, followed by the addition of NaOMe (1.79 mL of a 0.5 M solution in MeOH, 0.895 mmol). After 30 min, ICl (1.21 mL of a 0.5 M solution in CH_2Cl_2 , 1.21 mmol) was added to the mixture and stirred for 1 h. The reaction was warmed to room temperature, diluted with Et_2O (30 mL), washed with sodium metabisulphite (30 mL), water (30 mL), and brine (30 mL), dried (MgSO_4) and evaporated to give an orange oil. Purification by silica gel chromatography (EtOAc :pet. ether, 1:9, cooled to 0°C) yielded the product as a pale yellow oil (131 mg, 65%). $\nu_{\max}/\text{cm}^{-1}$ 2946, 1710, 1609, 1557, 1433, 1390, 1357, 1238, 1189 and 1152; ^1H NMR (500 MHz, CDCl_3) δ_{H} 2.31 (3H, d, $J = 1$, CH_3), 3.73 (3H, s, OCH_3), 5.87 (1H, s, CH), 6.28 (1H, d, $J = 15$, CH), 6.51 (1H, ddd, $J = 15$, 11 and 5, CH), 6.62 (1H, d, $J = 15$, CH), and 7.16 (1H, ddd, $J = 15$, 11 and 5, CH); ^{13}C NMR (126 MHz, CDCl_3) δ_{C} 13.8, 51.4, 83.4, 120.7, 133.8, 136.3, 145.0, 151.8, 167.5; m/z (ES) 277.9799 (M^+ , $\text{C}_9\text{H}_{11}\text{IO}_2$, requires 277.9798), 247, 219, 127, 91, 65 and 50.

(2*E*,4*E*,6*E*)-3-Methyl-9-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-nona-2,4,6-trien-8-ynoic acid methyl ester. The corresponding iodide (60 mg, 0.216 mmol), 6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 5 (55 mg, 0.26 mmol) and Et_3N (2 mL) were added to a dried Schlenk tube and the mixture degassed using the freeze–pump–thaw method (3 \times). $\text{Pd}(\text{OAc})_2$ (2.5 mg, 0.01 mmol), PPh_3 (5.5 mg, 0.02 mmol) and CuI (4 mg, 0.02 mmol) were then added and the mixture degassed using the freeze–pump–thaw method (3 \times) and stirred at room temperature for 5 h. The reaction was diluted with Et_2O (60 mL), passed through Celite, washed with 5% HCl (20 mL, 2 \times), brine (20 mL), dried (MgSO_4) and evaporated to give an orange oil. Purification by silica gel chromatography (pet. ether:EtOAc, 95:5, as eluent) gave (2*E*,4*E*,6*E*)-3-methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester as a pale yellow oil (50 mg, 64%). $\nu_{\max}/\text{cm}^{-1}$ 2955, 2181, 1709, 1604, 1435, 1358, 1240, and 1153; ^1H NMR (700 MHz, CDCl_3) δ_{H} 1.27 (6H, s, 2 \times CH_3), 1.28 (6H, s, 2 \times CH_3), 1.67 (4H, s, 2 \times CH_2), 2.31 (3H, s, CH_3), 3.71 (3H, s, OCH_3), 5.82 (1H, s, CH), 5.99 (1H, d, $J = 15$, CH), 6.34 (1H, d, $J = 15$, CH), 6.67 (1H, ddd, $J = 15$, 11 and 4, CH), 6.74 (1H, ddd, $J = 15$, 11 and 4, CH),

7.19 (1H, dd, $J = 8$ and 1.5, Ar), 7.27 (1H, d, $J = 8$, Ar), 7.39 (1H, d, $J = 1.5$, Ar); ^{13}C NMR (176 MHz, CDCl_3) δ_{C} 13.9, 31.9, 31.9, 34.6, 34.6, 35.1, 35.1, 51.3, 88.2, 95.5, 98.8, 115.0, 120.2, 120.4, 127.0, 128.8, 130.1, 134.0, 137.5, 140.6, 145.3, 146.1, 167.5; m/z (ES) 363.2322 ($\text{M} + \text{H}^+$, $\text{C}_{25}\text{H}_{31}\text{O}_2$, requires 363.2319). 331, 289 and 215.

(2*E*,4*E*,6*E*)-3-Methyl-9-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-nona-2,4,6-trien-8-ynoic acid 14. (2*E*,4*E*,6*E*)-3-Methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester (120 mg, 0.331 mmol) was added to a stirred solution of LiOH (42 mg, 0.993 mmol) in THF– H_2O (3:1, 10 mL) at 4°C . After the reaction was judged to be complete by tlc, the reaction mixture was acidified to pH 1/2 by 20% HCl, extracted with Et_2O (20 mL), dried (MgSO_4) and evaporated to give an orange oil. Purification by silica gel chromatography (petroleum ether:EtOAc, 9:1, as eluent) gave the product as a yellow solid (100 mg, 87%) and a 2.5:1 mixture of alkene diastereoisomers. ^1H NMR (700 MHz, CDCl_3) δ_{H} 1.26 (6H, s, 2 \times CH_3), 1.27 (6H, s, 2 \times CH_3), 1.67 (4H, s, 2 \times CH_2), 2.32 (3H, s, CH_3), 5.85 (1H, s, CH), 6.01 (1H, d, $J = 14$, CH), 6.36 (1H, d, $J = 14$, CH), 6.73 (2H, ddd, $J = 14$, 11 and 4, 2 \times CH), 7.19 (1H, dd, $J = 8$ and 1.5, Ar), 7.28 (1H, d, $J = 8$, Ar), 7.39 (1H, d, $J = 1.5$, Ar); ^{13}C NMR (176 MHz, CDCl_3) δ_{C} 14.1, 31.9, 31.9, 32.0, 34.4, 34.6, 35.1, 35.1, 88.1, 95.8, 99.0, 115.6, 119.4, 120.2, 126.9, 128.8, 130.2, 134.8, 137.2, 140.5, 145.4, 146.1, 154.4; m/z (ES) 347.2016 ($\text{M}^+ - \text{H}$, $\text{C}_{24}\text{H}_{27}\text{O}_2$, requires 347.2017).

Exposure to light

Synthetic retinoid NMR samples were prepared and left to stand in ordinary laboratory light, with additional irradiation from a standard fluorescent light *ca.* 30 cm above the sample.

Biological analytical procedures

Tissue culture. Human pluripotent TERA2.cl.SP12 embryonal carcinoma stem cells were maintained under standard laboratory conditions as previously described.³¹ In brief, cells were cultured in DMEM (Sigma) supplemented with 10% FCS (Gibco), 2 mM L-glutamine and 100 active units each of penicillin and streptomycin (Gibco). Cultures were passaged using acid-washed glass beads (VWR) unless a single-cell suspension was required for counting, in which case a 0.25% trypsin EDTA (Cambrex) solution was used. Cultures intended for flow cytometric and RT-PCR analysis were set up in T25 flasks (Nunc) while 12-well plates (Nunc) were used for immunocytochemical studies and cell viability/apoptotic analysis.

Flow cytometry. Flow cytometry analysis was carried out on live cells using antibodies recognising cell surface markers. The expression of markers indicative of the stem cell SSEA-3 (University of Iowa Hybridoma Bank) and TRA-1-60 (generous gift from Prof. P. Andrews, University of Sheffield) or neural cell (A2B5, R&D Systems) phenotype was determined to indicate the status of cellular differentiation by TERA2.cl.SP12 cells. Suspensions of single EC cells of their differentiated derivatives were formed by the addition of 1 mL 0.25% trypsin–EDTA solution. The cell suspension was divided accordingly for flow cytometry and RT-PCR (see later) analysis accordingly.



Cells were added to a 96-well plate (0.2×10^6 cells per well) as a suspension in wash buffer (0.1% BSA in PBS) for incubation with primary (1:20 SSEA-3 and TRA-1-60, or 1:10 A2B5) and FITC-conjugated secondary antibody (Cappel, 1:100) as previously described. Labelled cells were analysed in a Guave EasyCyte™ Plus System (Millipore) flow cytometer. Thresholds determining the numbers of positively expressing cells were set against the negative control antibody P3X.

Gene expression analysis. Real time PCR was carried out on cells immediately lysed after treatment with 0.25% trypsin-EDTA. Commercial RNA extraction kits and procedures (Qiagen) and reverse transcription procedures (Applied Biosystems) were followed. In brief, cells were lysed, homogenised using a 20-gauge needle, and passed through an RNeasy spin column. DNase digestion was carried out, before the RNA was extracted from the column as a suspension in RNase free water. Amounts of RNA extracted were determined using a Nanodrop Spectrophotometer ND-100™, followed by analysis on a 1% Agarose gel to check RNA integrity. Reverse transcription was then carried out using a high-capacity cDNA reverse transcription kit and a thermal cycler. cDNA was stored at -20°C prior to analysis. RT-PCR was performed using the TaqMan Gene Expression system from Applied Biosystems. Probe sets to the specific genes analysed were purchased from Applied Biosystems using the AB codes: Oct4 (Hs03005111_g1); Nanog (Hs02387400_g1); Pax-6 (Hs00240871_m1). GAPDH (4333764F) was used as the internal control gene. Sample reactions were performed in 96-well plates following the manufacturer's recommended protocol and were run on the Applied Biosystems 7500 Fast RT-PCR analyser.

FTIR microspectroscopy

The infrared data were recorded on a Varian 670 FTIR spectrometer interfaced with a Varian-620 imaging infrared microscope. The microscope was equipped with a 128×128 liquid nitrogen cooled MCT focal plane array detector (FPA) with a pixel effective size on the sample of $5.5\ \mu\text{m}$. The infrared spectral images were collected in transmission mode (512 scans at $4\ \text{cm}^{-1}$ resolution) and the background image was recorded from a clean CaF_2 slide. Data was processed using the same methods described by Clemens *et al.*³⁵

Acknowledgements

We thank the BBSRC and Reinnervate Ltd. for an industrial studentship (to A. P. H.) and the National Mass Spectrometry Service, Swansea. PG acknowledges STFC for funding of beamtime. GC acknowledges support from the School of Chemical Engineering and Analytical Science at UoM for a PhD scholarship.

References

- 1 M. B. Sporn, A. B. Roberts and D. S. Goodman, *The Retinoids*, Academic Press, Orlando, 2nd edn, 1984.
- 2 V. B. Christie, T. B. Marder, A. Whiting and S. A. Przyborski, *Mini-Rev. Med. Chem.*, 2008, **8**, 601–608.
- 3 M. Maden, *Nat. Rev. Neurosci.*, 2007, **8**, 755–765.
- 4 J. L. Napoli, *Clin. Immunol. Immunopathol.*, 1996, **80**, S52–S62.
- 5 S. A. Ross, P. J. McCaffery, U. C. Drager and L. M. De Luca, *Physiol. Rev.*, 2000, **80**, 1021–1054.
- 6 G. Wald, *Nature*, 1968, **219**, 800–802.
- 7 D. R. Soprano, P. Qin and K. J. Soprano, *Annu. Rev. Nutr.*, 2004, **24**, 201–221.
- 8 S. J. Freemantle, K. H. Dragnev and E. Dmitrovsky, *J. Natl. Cancer Inst.*, 2006, **98**, 426–427.
- 9 N. Lowe and R. Marks, *Retinoids: a Clinicians Guide*, London, 2nd edn, 1997.
- 10 V. B. Christie, J. H. Barnard, A. S. Batsanov, C. E. Bridgens, E. B. Cartmell, J. C. Collings, D. J. Maltman, C. P. F. Redfern, T. B. Marder, S. Przyborski and A. Whiting, *Org. Biomol. Chem.*, 2008, **6**, 3497–3507.
- 11 A. Murayama, T. Suzuki and M. Matsui, *J. Nutr. Sci. Vitaminol.*, 1997, **43**, 167–176.
- 12 D. K. Bempong, I. L. Honigberg and N. M. Meltzer, *J. Pharm. Biomed. Anal.*, 1995, **13**, 285–291.
- 13 T. Suzuki, S. R. Kunchala, M. Matsui and A. Murayama, *J. Nutr. Sci. Vitaminol.*, 1998, **44**, 729–736.
- 14 S. R. Kunchala, T. Suzuki and A. Murayama, *Indian J. Biochem. Biophys.*, 2000, **37**, 71–76.
- 15 F. Mavilio, A. Simeone, E. Boncinelli and P. W. Andrews, *Differentiation*, 1988, **37**, 73–79.
- 16 A. Simeone, D. Acampora, L. Arcioni, P. W. Andrews, E. Boncinelli and F. Mavilio, *Nature*, 1990, **346**, 763–766.
- 17 P. Venepally, L. G. Reddy and B. P. Sani, *Arch. Biochem. Biophys.*, 1997, **343**, 234–242.
- 18 R. W. Curley and J. W. Fowble, *Photochem. Photobiol.*, 1988, **47**, 831–835.
- 19 J. H. Barnard, J. C. Collings, A. Whiting, S. A. Przyborski and T. B. Marder, *Chem.-Eur. J.*, 2009, **15**, 11430–11442.
- 20 A. B. Roberts, M. D. Nichols, D. L. Newton and M. B. Sporn, *J. Biol. Chem.*, 1979, **254**, 6296–6302.
- 21 C. A. Frolik, M. B. Sporn and D. S. Goodman, *Metabolism of retinoids*, in *The Retinoids*, Academic Press, New York, 1984.
- 22 A. M. McCormick, J. L. Napoli, H. K. Schnoes and H. F. Deluca, *Biochemistry*, 1978, **17**, 4085–4090.
- 23 W. E. Piers, T. Wong, P. D. Coish and C. Rogers, *Can. J. Chem.*, 1994, **72**, 1816–1819.
- 24 A. S. Batsanov, J. P. Knowles and A. Whiting, *J. Org. Chem.*, 2007, **72**, 2525–2532.
- 25 R. Takeuchi, K. Tanabe and S. Tanaka, *J. Org. Chem.*, 2000, **65**, 1558–1561.
- 26 K. Sonogashira, Y. Tohda and N. Hagihara, *Tetrahedron Lett.*, 1975, 4467–4470.
- 27 K. Sonogashira, *J. Organomet. Chem.*, 2002, **653**, 46–49.
- 28 J. D. White, J. C. Amedio, S. Gut, S. Ohira and L. R. Jayasinghe, *J. Org. Chem.*, 1992, **57**, 2270–2284.
- 29 H. B. Zhai, Q. S. Chen, J. R. Zhao, S. J. Luo and X. S. Jia, *Tetrahedron Lett.*, 2003, **44**, 2893–2894.
- 30 J. Fogh and G. Trempe, *Human tumour cells in-vitro*, Plenum Press, New York, 1975.
- 31 S. Przyborski, *Stem Cells*, 2001, **19**, 500–504.
- 32 R. Stewart, L. Coyne, M. Lako, R. F. Halliwell and S. A. Przyborski, *Stem Cells Dev.*, 2004, **13**, 646–657.



- 33 R. Stewart, V. B. Christie and S. A. Przyborski, *Stem Cells*, 2003, **21**, 248–256.
- 34 S. A. Przyborski, I. E. Morton, A. Wood and P. W. Andrews, *Eur. J. Neurosci.*, 2000, **12**, 3521–3528.
- 35 G. Clemens, K. R. Flower, A. P. Henderson, A. Whiting, S. A. Przyborski, M. Jimenez-Hernandez, F. Ball, P. Bassan, G. Cinque and P. Gardner, *Mol. BioSyst.*, 2013, **9**, 677–692.
- 36 Z. Movasaghi, S. Rehman and I. Rehman, *Appl. Spectrosc. Rev.*, 2008, **43**, 134–179.
- 37 P. G. L. Andrus and R. D. Strickland, *Biospectroscopy*, 1998, **4**, 37–46.
- 38 A. Downes, R. Mouras and A. Elfick, *J. Biomed. Biotechnol.*, 2010, 1–10.
- 39 J. P. Knowles, V. E. O'Connor and A. Whiting, *Org. Biomol. Chem.*, 2011, **9**, 1876–1886.

